Prediction of age at menopause in women with polycystic ovary syndrome

Minooee, Sonia; Tehrani, Fahimeh Ramezani; Rahmati, Maryam; Mansournia, Mohammad Ali; Azizi, Fereidoun

doi:10.1080/13697137.2017.1392501

Cited by 40 publications

(31 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…17,26,27 The postulated menopausal age of women with PCOS, based on AMH, was approximately 2 years later than that of controls. 27 This is in line with our findings of the verified menopausal age, based on medical history and biochemistry.…”

Section: Discussionmentioning

confidence: 79%

“…23 The majority of the women had undergone ovarian surgery, including wedge resection, which reduced the ovarian reserve and had plausible secondary consequences for menopausal age. 17,26,27 The postulated menopausal age of women with PCOS, based on AMH, was approximately 2 years later than that of controls. It was found that a self-reported PCOS diagnosis was independently associated with delayed menopause, which is in line with the present study.…”

Section: Discussionmentioning

confidence: 99%

“…23 A recent epidemiological study of 61 936 women undergoing mammography in Sweden investigated whether common self-reported diseases affected the age of the natural menopause. 27 TA B L E 2 Gonadotropin levels, menopausal age and parity in women with polycystic ovary syndrome (PCOS) and controls. 19 However, neither of these studies reported on gonadotropin levels.…”

Section: Discussionmentioning

confidence: 99%

“…19,25 There have been attempts to calculate the menopausal age of women with and without PCOS based on AMH levels earlier in life. 17,26,27 The postulated menopausal age of women with PCOS, based on AMH, was approximately 2 years later than that of controls. 27 This is in line with our findings of the verified menopausal age, based on medical history and biochemistry.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Higher menopausal age but no differences in parity in women with polycystic ovary syndrome compared with controls

Forslund

Landin‐Wilhelmsen

Schmidt

et al. 2018

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Introduction To address the question of whether women with polycystic ovary syndrome (PCOS) reach menopause later than age‐matched controls, we conducted a follow‐up cohort study of women with well‐characterized PCOS that was diagnosed 24 years ago. The hypothesis was that women with PCOS would reach menopause later than non‐PCOS women. Parity during these 24 years was also studied. Material and methods Twenty‐seven women diagnosed with PCOS in 1992 (mean age 29.5 years) were re‐examined in 2016 (mean age 52.4 years). Randomly selected women, n = 94 (mean age 52.4 years), from the same geographic area included in the World Health Organization MONICA study, Gothenburg, Sweden, served as controls. Results The mean menopausal age in women with PCOS was higher than in controls (53.3 ± 2.2 years vs 49.3 ± 3.5 years, P < 0.01). Serum‐follicle stimulating hormone levels were lower in the PCOS women than in controls (31.0 ± 28.1 IU/L vs 52.3 ± 37.7 IU/L, P = 0.01). There was no difference in parity between women with PCOS (1.9 ± 1.3 children, range 0‐4) and controls (1.7 ± 1.0, range 0‐4 children). Conclusions Women with PCOS reached menopause 4 years later and had lower serum‐follicle stimulating hormone compared with age‐matched controls. Neither parity nor nulliparity differed between women with PCOS and controls.

show abstract

Section: Discussionmentioning

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Higher menopausal age but no differences in parity in women with polycystic ovary syndrome compared with controls

Forslund

Landin‐Wilhelmsen

Schmidt

et al. 2018

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

show abstract

“…Слід зазначити, що за даними окремих досліджень, вік менопаузи в жінок із СПКЯ є більшим порівняно з жінками без СПКЯ, вірогідно внаслідок високих рівнів антимюллерового гормону (АМГ) [36,37]. У дослідженні Y.S.…”

Section: особливості синтезу андрогенів в менопаузіunclassified

Androgen synthesis in menopause and diagnosis of causes of hyperandrogenism in menopause

Бурка¹,

Тутченко²

2019

Reproductive Endocrinology

View full text Add to dashboard Cite

Pathways coordinating oocyte attrition and abundance during mammalian ovarian reserve establishment

Grive

2020

Molecular Reproduction Devel

View full text Add to dashboard Cite

The mammalian ovarian reserve is comprised of a finite pool of primordial follicles, representing the lifetime reproductive capacity of females. In most mammals, the reserve is produced during embryonic and early postnatal development with oocyte numbers peaking during mid‐to‐late gestation, and then experiencing a dramatic decline continuing until shortly after birth. Oocytes remaining after the bulk of this attrition are subsequently surrounded by a layer of somatic pre‐granulosa cells with these units then referred to as “primordial follicles.” The complex and varied cell death mechanisms intrinsic to this process are not only characteristic of, but also essential for, the proper formation of this pool of follicles, and as a result must be immaculately balanced to ensure long‐term fertility and reproductive health. Too few follicles can lead to Primary Ovarian Insufficiency, resulting in fertility loss and other features of aging, such as an overall shorter lifespan. On the other hand, whereas an excess of follicles might extend reproductive lifespan, this might also be the underlying etiology of other ovarian pathologies. The last decade, in particular, has vastly expanded our understanding of oocyte attrition and determinants of ovarian reserve abundance. By continuing to decipher the intricacies underlying the cell death processes and development of the initial primordial follicle pool, we may be in a much better position to understand idiopathic cases of premature follicle depletion and improve ovarian health in reproductive‐age women.

show abstract

Prediction of age at menopause in women with polycystic ovary syndrome

Abstract: These findings provide the insight that, as reflected through significantly higher average levels of AMH in PCOS women, their predicted reproductive lifespan could be 2 years longer than their normo-ovulatory counterparts.

Cited by 40 publications

References 32 publications

Higher menopausal age but no differences in parity in women with polycystic ovary syndrome compared with controls

Higher menopausal age but no differences in parity in women with polycystic ovary syndrome compared with controls

Androgen synthesis in menopause and diagnosis of causes of hyperandrogenism in menopause

Pathways coordinating oocyte attrition and abundance during mammalian ovarian reserve establishment

Contact Info

Product

Resources

About